| Bioactivity | DAMGO is a μ-opioid receptor (μ-OPR ) selective agonist with a Kd of 3.46 nM for native μ-OPR[1]. | ||||||
| Invitro | DAMGO (1-10 μM) significantly reduces the activation of neuronal Akt and ERK1/2 by CXCL12 and inhibits CXCL12-promoted neuronal survival, but does not down-regulate CXCR4 protein expression[2].DAMGO (1 μM) effectively inhibits the prostaglandin E 2 (PGE 2) induced increase in a tetrodotoxin-resistant voltage-gated Na+ current (TTX-R I Na), i.e. PGE 2 (1 μM) can increase the TTX-R I Na peak by 103 % compared to 24.9 % with the addition of DAMGO[3]. | ||||||
| Name | DAMGO | ||||||
| CAS | 78123-71-4 | ||||||
| Sequence | Tyr-{d-Ala}-Gly-{Me-Phe}-Gly-ol | ||||||
| Shortening | Y-{d-Ala}-G-{Me-Phe}-G-ol | ||||||
| Formula | C26H35N5O6 | ||||||
| Molar Mass | 513.59 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture and light
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |